Olema Pharmaceuticals (OLMA) Net Cash Flow (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Net Cash Flow data on file, last reported at $4.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $4.2 million, up 104.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 88.73% YoY), and the FY2025 annual result was -$91.2 million, down 228.53% from the prior year.
• Net Cash Flow slipped to $4.2 million in Q1 2026 per OLMA's latest filing, from $13.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $103.6 million in Q4 2024 and troughed at -$88.8 million in Q1 2025.
• A 5-year average of $2.3 million and a median of $2.3 million in 2022 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 3519.36% in 2023 and fell as far as 1475.37% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$3.1 million in 2022, then tumbled by 1475.37% to -$48.9 million in 2023, then soared by 311.98% to $103.6 million in 2024, then sank by 87.41% to $13.0 million in 2025, then sank by 67.44% to $4.2 million in 2026.
• Business Quant data shows OLMA's Net Cash Flow at $4.2 million in Q1 2026, $13.0 million in Q4 2025, and -$17.2 million in Q3 2025.